BHCM
SGMT icon

Brevan Howard Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Brevan Howard Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,905
Closed -$109K – 2532
2026
Q1 		$109K Buy
+20,905
New +$117K ﹤0.01% 2004

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Brevan Howard Capital Management's SGMT Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 20,905 shares — an estimated $109K sold.

Brevan Howard Capital Management first reported a position in SGMT in Q1 2026 and held it in 1 quarter. The position peaked at $109K in Q1 2026. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 20,905 Sagimet Biosciences shares in Q2 2026, an estimated $109K.
  • Brevan Howard Capital Management first reported a position in Sagimet Biosciences in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Sagimet Biosciences position peaked at $109K in Q1 2026.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.